Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapes...( BELLEVILLE ON July 10 / Bioniche ...),Health

BELLEVILLE, ON, July 10 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, presented data regarding its E. coli O157:H7 cattle vaccine at the XXV World Buiatrics Congress in Budapest, Hungary today. The presentation was made by Dr. Dragan Rogan, Vice-President, Bioniche Animal Health Research & Development. It was entitled, "Vaccination of Cattle with E. coli O157:H7 Type III Secretion Proteins as a Pre-Slaughter Intervention Method to Reduce E. coli O157:H7 Prevalence", and was co-authored by Dr. David Smith, Dr. Rod Moxley, Dr. Andy Potter and Julie Yome.

The World Buiatrics Congress is the largest event of its kind in the cattle industry, and is attended by scientists from universities and research institutes, practitioners working with dairy and beef cattle and other ruminants, consultants, post-docs, PhDs and graduate students of veterinary medicine and animal science from around the world.

The Bioniche vaccine is the world's first vaccine that may be used as an on-farm intervention to reduce the amount of E. coli O157:H7 shed by cattle. Bioniche and its collaborators have been moving the vaccine towards commercial availability for eight years and it has been extensively tested at the University Nebraska-Lincoln, with efficacy results now being published in peer-reviewed scientific journals, most recently, the Journal of Food Protection, in November, 2007.

In his presentation in Budapest, Dr. Rogan summarized numerous studies that have been completed with the Bioniche vaccine over the last five years involving more than 30,000 cattle. In one study, calves were vaccinated with three doses and challenged with E. coli O157:H7 14 days later. There was a 2.28 log10 reduction in the magnitude of shedding in vaccinated animals compared to controls. In another study, with a three-dose vaccination and natural exposure to E. coli O157:H7, vaccinated animals w
'/>"/>